NL-OMON23699已完成不适用
Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA study.
BOOG study center0 个研究点目标入组 1,050 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,050
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with loco-regional recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent and for whom chemotherapy is not clinically indicated.
排除标准
- •1. Patients with advanced, symptomatic, visceral spread, who are at risk of life-threatening complications in the short term.
研究者
相似试验
进行中（未招募）
1 期
Endocrine therapy plus CDK4/6 inhibitor in first or second line for hormone receptor positive advanced breast cancerhormone receptor positive advanced breast cancerEUCTR2017-002334-23-NLDutch Breast Cancer Research Group (BOOG)1,050
已完成
3 期
Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA trialMammary carcinoma10006291Breast cancerNL-OMON53036BOOG Study Center1,050
尚未招募
不适用
Optimal therapeutic strategies with CDK4/6 inhibitors based on the real world evidence in patients with HR-positive/HER2-negative advanced and metastatic breast cancerHormone receptor positive HER2 negative advanced metastatic breast cancerJPRN-UMIN000051975Japan Breast Cancer Research Group(JBCRG)400
招募中
不适用
Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational studybreast cancerJPRN-UMIN000035533Setouchi Breast Project Comprehensive Support Organization75
进行中（未招募）
1 期
Inhibition of kinases CDK4/6 by Palbociclib in locally advanced/metastatic chordomaEUCTR2016-004660-19-DEniversity Hospital Heidelberg43